Clinical Trial Update: A Multicenter Randomized Controlled Phase II Trial of Iparomlimab and Tuvonralimab (QL1706) Combined with SOX Chemotherapy Versus Chemotherapy Alone in the Treatment of Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma [Phase 2]

View source ↗

Summary

A Phase II multicenter randomized trial evaluating iparomlimab and tuvonralimab (QL1706) added to SOX chemotherapy vs chemotherapy alone for locally advanced ga…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Cancer

Drugs mentioned

• OXALIPLATIN (Oxaliplatin)
• S-1 (tegafur/gimeracil/oteracil)
• Tuvonralimab (tuvonralimab)
• iparomlimab

Snippet

Sponsor: Shandong Provincial Hospital | Conditions: Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma | Phase 2 | Status: NOT_YET_RECRUITING